New antiretroviral drugs

Current HIV/AIDS Reports

Volumn 3, Issue 2, 2006, Pages 93-101

  Hanson, Kimberly ^a   Hicks, Charles ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 O (3', 3'DIMETHYLSUCCINYL) BETULINIC ACID; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTIVIRUS AGENT; APLAVIROC; BETULIC ACID; BRECANAVIR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DARUNAVIR; EFAVIRENZ; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE INHIBITOR; MARAVIROC; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CCR5 ANTAGONIST; PRO 140; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIFURVITIDE; TENOFOVIR; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC;

CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HALF LIFE TIME; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33750321164     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-006-0024-z     Document Type: Review

References (58)

1. Mahungu T, Ballinger J, Swaden L, et al.: Switching to Saquinavir 500/r-based regimens in subjects on HAART is not associated with loss of virologic control [abstract# PE1.1/5]. Paper presented at the 10th European AIDS Conference. Dublin, Ireland; November 17-20, 2005.
2. Awni W, Chiu Y-L, Zhu T, et al.: Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation [abstract# We0206]. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
3. Geleziunas R, Gallagher K, Zhang H, et al.: HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′- dideoxy-2′,3′-didehydro-5-fluorocytidine (Reverset). Antivir Chem Chemo 2003, 14:49-59.
4. Hammond JL, Parikh UM, Koontz DL, et al.: In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine. Antimicrob Agents Chemother 2005, 49:3930-3932.
5. Murphy RL, Schürmann JD, Kravec I, et al.: Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients [abstract# 545]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-17, 2003.
6. Murphy RL, Schürmann D, Beard A, et al.: Potent anti-HIV-1 activity of Reverset™ following 10 days of monotherapy in treatment-naive individuals [abstract# MoOrB1056]. Paper presented at the 15th International AIDS Conference. Bangkok, Thailand; July 11-16, 2004.
7. Cohen C, Katlama C, Murphy R, et al.: Antiretroviral activity and tolerability of Reverset (D-d4FC), a new fluorocytidine nucleoside analog, when used in combination therapy in treatment-experienced patients: results of phase IIb study RVT-203 [abstract# WeOaLB0103]. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
8. Bethell R, Collins P, Holdich T, et al.: In vitro and in vivo antiviral activity of SPD754 against wild-type and NRTI-resistant viruses [abstract# WePeA5642]. Paper presented at the 15th International AIDS Conference. Bangkok, Thailand; July 11-16, 2004.
9. Holdich T, Dennis K: Influence of food upon the pharmacokinetics of SPD754 [abstract# 119]. Paper presented at the 9th European AIDS Conference. Warsaw, Poland; October 25-29, 2003.
10. Bethell R, Adams J, De Muys J, et al.: Pharmacological evaluations of a dual deoxycytosine analogue combination: 3TC and SPD754 [abstract #138]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infection. San Francisco, CA; February 8-11, 2004.
11. Cahn P, Lange J, Cassetti I, et al.: Anti HIV-1 activity of SPD754 a new NRTI: Results of a 10 day monotherapy study in treatment naïve HIV patients [abstract# LB15]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-17, 2003.
12. Bethell RC, Collins P: Genotypic and phenotypic analysis of HIV-1 isolates from patients after 10 days monotherpay with SPD754 [abstract# 268]. Paper presented at the 44th Interscience Conference on Antimicrobial Agents Chemotherapy. Washington, DC; October 30-November 2, 2004.
13. Das K, Clark AD Jr, Lewi PJ, et al.: Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004, 47:2550-2560.
14. Andries K, Azijn H, Thielemans T, et al.: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:4680-4686.
15. Piscitelli S, Baede P, Vant Klooster G, et al.: Pharmacokinetics of TMC 125 in HIV-infected patients and healthy volunteers [abstract# 5.3]. Paper presented at the 3rd International Workshop on the Clinical Pharmacology of HIV Therapy. Washington, DC; April 11-13, 2002.
16. Gruzdev B, Rakhmanova A, Doubovskaya E, et al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003, 17:2487-2494.
17. Gazzard BG, Pozniak AL, Rosenbaum W, et al.: An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003, 17:49-54.
18. Montaner J, Domingo P, Junod P, et al.: Safety and tolerability of TMC125 in 3-class-experienced HIV-infected patients: 24-week primary analysis of trial TMC125-C203 [abstract# LBPS3/7B]. Paper presented at the 10th European AIDS Conference. Dublin, Ireland; November 17-20, 2005.
19. Nadler JP, Grossman HA, Hicks C, et al.: Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-C223 [abstract# LBPS3/7]. Paper presented at the 10th European AIDS Conference. Dublin, Ireland; November 17-20, 2005.
20. de Bethume MP, Andries K, Azijn H, et al.: TMC278, a new potent NNRTI, with an increased barrier to resistance and favorable pharmacokinetic profile [abstract# 556]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infection. Boston, MA; February 22-25, 2005.
21. Hoetelmans R, Van Heeswijk R, Kestens D, et al.: Effect of food and multiple-dose pharmacokinetics of TNC278 as an oral tablet formulation [abstract# TuPe3.1B10]. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
22. Goebel F, Yakovlev A, Pozniak A, et al.: TMC278: Potent anti-HIV activity in antiretroviral therapy-naïve patients [abstract# 160]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infection. Boston, MA; February 22-25, 2005.
23. De Meyer S, Azijn H, Surleraux D, et al.: TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005, 49:2314-2321.
24. van der Geest R, van der Sandt I, Gille D, et al.: Safety, tolerability and pharmacokinetics of escalating single oral doses of TMC 114, a novel protease inhibitor (PI) highly active against HIV-1 variants resistant to other PIs [abstract# I-1934]. Paper presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; December 16-19, 2001.
25. Katlama C, Carvalho MTM, Cooper D, et al.: TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC114-C213) [abstract# WeOaLB0102]. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005
26. Grinsztejn B, Arasteh K, Clotet B, et al.: TMC114/ritonavir is well tolerated in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMCH4-C213) [abstract# WeOaLB6.2C01]. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
27. Wilkin T, Haubrich R, Steinhart CR, et al.: TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the power 2 study (C2020) [abstract# H-413]. Paper presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 15-19, 2005.
28. Ward D, Lalezari J, Thompson M, et al.: Preliminary activity and safety of 640385/ritonavir in HIV-infected patients (Study HPR10006); an 8-week interim analysis [abstract# H-412]. Paper presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 15-19, 2005.
29. Dai SJ, Dou GF, Qiang XH, et al.: Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 2005, 26:1274-1280.
30. Lin P, Blair W, Wang T, et al.: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A 2003, 100:11013-11018.
31. Moore PL, Cilliers T, Morris L: Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. AIDS 2004, 18:2327-2330.
32. Burkly LC, Olson D, Shapiro R, et al.: Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992, 149:1779-1787.
33. Godofsky E, Zhang X, Sorensen M, et al.: In vitro antiretroviral activity of the humanized anti-CD4 monoclonal antibody, TNX-355, against CCR5, CXCR4, and dual-tropic isolates and synergy with enfuvirtide [poster# 3844]. Poster presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 15-19, 2005.
34. Reimann KA, Burkly LC, Burrus B, et al.: In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AJDS Res Hum Retroviruses 1993, 9:199-207.
35. Reimann KA, Khunkhun R, Lin W, et al.: A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002, 18:747-755.
36. Kuritzkes DR, Jacobson J, Powderly WG, et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004, 189:286-291.
37. Reimann KA, Lin W, Bixler S, et al.: AIDS Res Hum Retroviruses 1997, 13:933-943.
38. Jacobson JM, Kuritzkes DR, Godofsky E, et al.: A phase I multiple dose study of the anti-CD4 monoclonal antibody, TNX-355, in multiple doses in HIV-infected subjects [abstract# 536]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
39. Norris D, Morales J, Gathe J, et al.: TNX-355 in combination with optimized background regimen (OBR) exhibits greater antiviral activity than OBR alone in HIV-treatment experience patients. Paper presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 15-19, 2005.
40. Macartney MJ, Dorr PK, Smith-Burchnell C, et al.: In vitro antiviral profile of UK-427,857: a novel CCR5 antagonist [abstract# H-875]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003.
41. McHale M, Abel S, Russell D, et al.: Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857) [abstract# TuOa0204]. Paper presented at the 3rd International AIDS Society. Rio de Janeiro, Brazil; July 24-27, 2005.
42. Fatkenheuer G, Pozniak L, Johnson M, et al.: Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857 a novel CCR5 antagonist [abstract#TuPeB4489]. Paper presented at the 15th International AIDS Conference. Bangkok, Thailand; July 11-16, 2004.
43. Pozniak AL, Fatkenheuer G, Johnson M, et al.: Effect of short term monotherapy with UK-427,857 on viral load in HIV-infected patients [abstract# H-443]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003.
44. Rosario MC, Poland W, Felstead S, et al.: Modeling of UK-427,857, a novel CCr5 antagonist, efficacy in short-term monotherapy [abstract# TuPeB4479]. Paper presented at the 15th International AIDS Conference. Bangkok, Thailand; July 11-16, 2004.
45. Fatkenheuer G, Pozniak AL, Johnson MA, et al.: Efficacy of short-term monotherapy with maraviroc, a new CCr5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11:1170-1171.
46. Westby M, Whitcomb J, Huang W, et al.: Reversible predominance of CXCR4 utilizing variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857 [abstract #538]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
47. Baroudy B: Coreceptor inhibitors [abstract# MoOrAI38]. Paper presented at the 14th International AIDS Conference. Barcelona, Spain; July 7-12, 2002.
48. Schurmann D, Rouzier R, Nougarede R, et al.: SCHD: antiviral activity of a CCR5 receptor antagonist [abstract# 140LB]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
49. Roschke V, Clark S, Branco L, et al.: Characterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and block HIV-1 entry [abstract #2871]. Paper presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 30-November 2, 2004.
50. Olson WC, Rabut GE, Nagashima KA, et al.: Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999, 73:4145-4155.
51. Trkola A, Ketas TJ, Nagashima KA, et al.: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001, 75:579-588.
52. Murga J, Olson W, Pevear DC: Antiviral synergy between the CCR5 mAb PRO 140 and small-molecule CCR5 antagonists [abstract# TuOa0206]. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
53. Schols D, Claes S, Hatse S, et al.: Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist [abstract# 563]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10-14, 2003.
54. Schols D, Vermeire K, Hatse S, et al.: In vitro anti-HIV activity profile of AMD887, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD070 [abstract# 539]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
55. Stone N, Dunaway S, Flexner C, et al.: Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects [abstract# TuPeB4475]. Paper presented at the 15th International AIDS Conference. Bangkok, Thailand; July 11-16, 2004.
56. Morales-Ramirez JO, Teppler H, Kovacs C, et al.: Antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in ART-naive HIV-1 infected patients [abstract # LBPS1/6]. Paper presented at the 10th European AIDS Conference. Dublin, Ireland; November 17-20, 2005. Along with Li et al. [57], this paper represents first-in-class agents targeting new steps in the HIV life cycle.
57. Li F, Goila-Guar R, Salzwedel K, et al.: PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Nat Acad Sci 2003, 100:13555-13560. Along with Morales-Ramirez et al. [56], this paper represents first-in-class agents targeting new steps in the HIV life cycle.
58. Beatty G, Lalezari J, Eron J, et al.: Safety and antiviral activity of PA-457, the first in class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients [abstract# H-416d]. Paper presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 15-19, 2005.